InvestSMART

pSivida Limited (ASX: PSD) - Announcements

DELISTED - Current share price for PSD : $0.093

ASX company news and announcements for pSivida Limited (PSD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All pSivida Limited (PSD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than pSivida Limited (PSD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for pSivida Limited (PSD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- In Negotiation with biotech fund for $A33.7M investment 10 Nov 2006 10:09AM $0.295 $0.093 fallen by 68.47%
- Commitments Test Entity - First Quarter Report 31 Oct 2006 8:13PM $0.290 $0.093 fallen by 67.93%
- Initiation of Phase II clinical study of new product 19 Sep 2006 12:34PM $0.300 $0.093 fallen by 69%
- Completes agreement with existing Note Holder 15 Sep 2006 10:44AM $0.300 $0.093 fallen by 69%
- Preliminary Final Report 14 Sep 2006 8:29AM $0.305 $0.093 fallen by 69.51%
- Secures additional US$6.5m funding 31 Jul 2006 9:57AM $0.340 $0.093 fallen by 72.65%
- Commitments Test Entity - Fourth Quarter Report 31 Jul 2006 9:48AM $0.350 $0.093 fallen by 73.43%
- BioSilicon Demonstrates Adjuvant Properties 5 Jul 2006 9:41AM $0.530 $0.093 fallen by 82.45%
- BioSilicon Breakthrough 8 Jun 2006 9:56AM $0.590 $0.093 fallen by 84.24%
- Govt Approvals for International Phase 3 trials for Medidur 7 Jun 2006 9:54AM $0.600 $0.093 fallen by 84.50%
- BrachySil Regulatory Approval for European Pancreatic Trial 30 May 2006 9:59AM $0.600 $0.093 fallen by 84.50%
- Expansion of BrachySil Liver Cancer Clinical Trial 25 May 2006 10:06AM $0.560 $0.093 fallen by 83.39%
- Prospectus for a Non-renounceable Rights Offer 11 May 2006 6:30PM $0.590 $0.093 fallen by 84.24%
- Rights Issue to fund late stage Macular Edema trials 2 May 2006 1:39PM $0.570 $0.093 fallen by 83.68%
- Commitments Test Entity - Third Quarter Report 28 Apr 2006 1:43PM $0.570 $0.093 fallen by 83.68%
- Positive European Trial Results for Retisert 6 Apr 2006 9:50AM $0.710 $0.093 fallen by 86.90%
- New evaluation agmt for cardiovascular drug delivery 5 Apr 2006 9:29AM $0.700 $0.093 fallen by 86.71%
- Retisert slows progression of Diabetic Retinopathy in trials 3 Apr 2006 9:47AM $0.720 $0.093 fallen by 87.08%
- Open Briefing: pSivida Update on Progress 22 Mar 2006 9:36AM $0.725 $0.093 fallen by 87.17%
- DSMB Recommends Continuation of Medidur Clinical Trials 21 Mar 2006 9:52AM $0.705 $0.093 fallen by 86.81%
- Medidur Manufacture Certified to be GMP Equivalent to EU 20 Mar 2006 10:00AM $0.695 $0.093 fallen by 86.62%
- Half Yearly Report/Half Year Accounts 16 Mar 2006 8:40PM $0.700 $0.093 fallen by 86.71%
- Response to ASX Query re: Share Price 16 Mar 2006 2:56PM $0.785 $0.093 fallen by 88.15%
- Uveitis long term trial results positive 21 Feb 2006 10:01AM $0.705 $0.093 fallen by 86.81%
- Novartis to Co-Promote Retisert With Bausch & Lomb 10 Feb 2006 9:43AM $0.640 $0.093 fallen by 85.47%

51 - 75 of 141 results

Page 3 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.